| Document |
Document Title |
|
WO/1999/005277A1 |
The present invention relates to a recombinant expression vector which is prepared by inserting a human parathyroid hormone gene containing a urokinase-specific cleavage site into an L-arabinose inducible vector containing a phosphoribul...
|
|
WO/1999/002185A1 |
A composition which elicits antibodies to greater than 95 %, and even greater than 99 %, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HI...
|
|
WO/1999/000670A1 |
The present invention relates to methods for covalent immobilisation of biomolecules to carriers and membranes, wherein the presence of a His-tag is exploited, and wherein the amino acid residues that comprise said His-tag are directly i...
|
|
WO/1999/000489A1 |
The present invention relates to modified polypeptides with reduced respiratory allergenicity having coupled polymeric molecules with a molecular weight from 100 up to 750 Da, covalently to the parent polypeptide having a molecular weigh...
|
|
WO/1998/058967A1 |
This invention describes self assembled monolayers (SAMs) manufactured by imprinting reactive peptides onto solid supports. The invention further relates to methods of preparing and using these improved SAMs.
|
|
WO/1998/058293A2 |
The invention relates to a method and a device for immobilizing macromolecules according to the generic part of claims 1 and 19, 20, 21 and 22. The aim of the invention is to enable light induced, addressable immobilization of bio-macrom...
|
|
WO/1998/054213A2 |
The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous sy...
|
|
WO/1998/044114A1 |
The present invention provides a human calcium-binding protein (HCBP) and polynucleotides which identify and encode HCBP. The invention also provides expression vectors and host cells, agonists, antibodies, and antagonists. In addition, ...
|
|
WO/1998/041562A1 |
Branched, substantially non-antigenic polymers are disclosed. Conjugates prepared with the polymers and biologically active molecules such as proteins and peptides demonstrate extended circulating life $i(in vivo). Substantially fewer si...
|
|
WO/1998/040738A1 |
The present invention relates to improved prostate specific antigen substrates, and provides for a method of purifying such substrates as well as compositions comprising the substrates themselves. These substrates may be used in assays w...
|
|
WO/1998/040469A1 |
The present invention relates to a monoclonal antibody reactive with human serum albumin (HSA) in a manner such that when the monoclonal antibody is bound to HSA, the HSA retains its ability to prevent cell attachment. The present invent...
|
|
WO/1998/040409A1 |
Processes for conjugating proteins with polyethylene glycol are disclosed. The disclosed processes provide modified proteins having little or no decrease in their activity and include the steps of protecting one or more sites on the prot...
|
|
WO/1998/037053A1 |
A novel receptor which is not of the RAR type that binds AHPN and believed to be involved in apoptosis is provided. This receptor is useful for identifying ligands that induce apoptosis.
|
|
WO/1998/037222A1 |
A method for the preparation of oligo- and/or polysaccharides, which are essentially homogenous with respect to the length of a carbohydrate chain and/or the respective molecular weight, from a sample having precursors of the oligo- and/...
|
|
WO/1998/037085A1 |
The invention provides methods and compositions relating to vertebrate UNC-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins. The proteins may be produced recombinantly from transformed host c...
|
|
WO/1998/034968A1 |
The present invention provides polymers incorporating peptides. In a first embodiment the polymers comprise polymerised units of (1) CH�2?=CR�4?-CO-X-R�1? and (2) CH�2?=CR�3?-CO-R�2?, and optionally one or more other monomers...
|
|
WO/1998/033808A2 |
Compositions comprised of at least two biopolymers (e.g., nucleic acids or polypeptides), which are conjugated to an insoluble support by two different reversible linkages, which are cleavable under selective conditions, as well as metho...
|
|
WO/1998/031791A1 |
The present invention is concerned with a fragment of IgA1-protease having 40 to 200 amino acid residues and comprising at least 40 amino acids of an amino acid sequence as shown in SEQ ID NO 1, beginning with the amino acid in any one o...
|
|
WO/1998/031801A1 |
The present invention relates to a novel I-FLICE-1 or I-FLICE-2 protein which is a novel inhibitor of TNFR-1 and CD-95 induced apoptosis. In particular, isolated nucleic acid molecules are provided encoding the human I-FLICE-1 or I-FLICE...
|
|
WO/1998/030239A2 |
A process for preparing a protein-polysaccharide conjugate includes racting a protein with a polysaccharide to produce a mixture including a protein-polysaccharide conjugate and free protein. At least one unreacted reagent or low molecul...
|
|
WO/1998/026793A1 |
Compositions of the current invention are directed toward inhibiting the growth of microorganisms, particularly fungi. The compositions consist of chemically-synthesized antibiotics comprising certain amino acids. Methods of identifying ...
|
|
WO/1998/027115A1 |
A method for the separation of a target molecule from a mixture is described. The method employs oil bodies and their associated proteins as affinity matrices for the selective, non-covalent binding of desired target molecules. The oil b...
|
|
WO/1998/025965A2 |
Described are peptides and compounds that bind to and activate the thrombopoietin receptor. Such peptides and compounds are useful in methods for treating haematological disorders and particularly, thrombocytopenia resulting from chemoth...
|
|
WO/1998/024297A1 |
The present invention relates to a method of imparting pathogen resistance to plants. This involves applying a hypersensitive response elicitor polypeptide or protein in a non-infectious form to a plant seed under conditions where the po...
|
|
WO/1998/022583A1 |
The present invention provides the amino acid and nucleotide sequence of a protein that binds to $g(b)3 integrins, $g(a)IIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention pr...
|
|
WO/1998/020043A1 |
The subject invention provides new materials and methods for the efficient isolation and purification of stem cells. Specifically, conductive immunopolymers with stem cell specific antibodies can be used to remove systems from biological...
|
|
WO/1998/020019A1 |
Compositions containing at least one bead conjugated to a solid support and further conjugated to at least one macromolecule, such as a nucleic acid and methods for making the compositions are provided. The resulting surfaces formed from...
|
|
WO/1998/015658A1 |
Methods and compositions for treatment, diagnosis, and prevention of a virus comprise administering to a patient antibodies which react with regions of viral proteins and result in neutralization of infectivity and inactivation of functi...
|
|
WO/1998/015833A1 |
The invention provides novel methods and means for selecting peptides and for other proteinaceous molecules having specific binding affinity for a target. The binding peptides/proteins are displayed on replicable display packages, prefer...
|
|
WO/1998/015572A1 |
A novel generic coating procedure to improve the coating efficienncy of small synthetic peptide antigens in ELISA is described. Inthis invention the binding capacities of several peptides linked to various moieties were compared to their...
|
|
WO/1998/014463A1 |
Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.
|
|
WO/1998/012561A1 |
A method and kit for the diagnosis and quantification of the state of oxidation, and more specifically, the level of lipid peroxidation, of a host is provided that includes contacting a host biological sample with an antibody to an antig...
|
|
WO/1998/009735A1 |
A method is proposed with which chemically defined bodies can be deposited on a substrate. Therefore, the bodies are fixed with a predetermined orientation on a stamping means which is then approached to the substrate whereby the bodies ...
|
|
WO/1998/006737A1 |
Engineered fluorescent proteins, nucleic acids encoding them and methods of use.
|
|
WO/1998/005363A2 |
This invention provides compositions consisting essentially of a polypeptide and a water-soluble polymer covalently bound thereto at the N-terminal $g(a)-carbon atom via a hydrazone or reduced hydrazone bond, or an oxime or reduced oxime...
|
|
WO/1998/001466A1 |
The invention relates to imprint polypeptides covalently cross-linked and having a fixed and stabilised arrangement, process for the preparation and uses thereof. The properties of said imprint polypeptides (VIP) covalently cross-linked ...
|
|
WO/1998/001496A1 |
The invention concerns the preparation of azlactone-derivatized polyamides which are obtained by reacting polyamides with a solution containing an azabicyclo compound and a vinyl azlactone derivative of formula (I), in which R?1�, R?2ï...
|
|
WO/1998/000156A1 |
Phosphopeptides which significantly reduce bone loss or weakening are provided by the invention. A method for treating or preventing any conditions associated with bone loss or weakening by administering the phosphopeptides by oral or in...
|
|
WO/1998/000531A1 |
A method of preparing polyphosphazene microspheres wherein the polyphosphazene microspheres are produced by coacervation. In one embodiment, a solution containing a polyphosphazene is admixed with a dehydration agent, such as a solution ...
|
|
WO/1997/046259A2 |
The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting m...
|
|
WO/1997/046590A1 |
The present invention is directed to support members having surfaces that are rendered hydrophilic for use as a substrate for the immobilization of bioactive species thereon. The hydrophilic surfaces are chemically stable on the support ...
|
|
WO/1997/044052A1 |
Compounds having immunomodulatory activity which are peptide-type compounds, or variants of fragments thereof, including the N-terminal acylated and C-terminal amidated or esterified forms of up to 30 amino acids wherein the peptide-type...
|
|
WO/1997/040147A1 |
The present provides immunogenic HAV peptides, antibodies and assays for detecting HAV. Vaccines against HAV are also provided.
|
|
WO/1997/039761A1 |
A process for the viral inactivation of lyophilized blood proteins, particularly Factor VIII, by heat comprising forming a stable complex between the blood protein and a cyclodextrin in an aqueous solution. The solution is then lyophiliz...
|
|
WO/1997/038703A1 |
Disclosed is a chimeric isoprenoid synthase polypeptide including a first domain from a first isoprenoid synthase joined to a second domain from a second, heterologous isoprenoid synthase, whereby the chimeric isoprenoid synthase is capa...
|
|
WO/1997/038731A1 |
The present invention provides for immunoliposomes that optimizes internalization of a drug into target cells bearing a characteristic cell surface marker. The immunoliposomes comprise a Fab' domain of an antibody that specifically binds...
|
|
WO/1997/038125A1 |
The invention provides diagnostic and prognostic methods which comprise determining the level of expression of the tumor suppressor gene pRb2/p130. Because the relative level of pRb2/p130 expression correlates with the presence of cancer...
|
|
WO/1997/037223A1 |
Novel polypeptides having WW domains of interest are described, along with DNA sequences that encode the same. A method of identifying these polypeptides by means of a sequence-independent (that is, independent of the primary sequence of...
|
|
WO/1997/036614A1 |
Polymers and polymer conjugates comprising cross-linked Staphyloccocal protein A, or cross-linked protein A-superantigen, or cross-linked functional derivatives thereof ranging in size from 12 kDa to 10,000 kDa are useful in the treatmen...
|
|
WO/1997/035886A1 |
An homologous complement restriction factor (HCRF) can be bound to a target surface and used to prevent or reduce activation of complement. This is particularly useful for coating medical apparatuses which are used to transport or treat ...
|
